British mother revealed to have died of food poisoning in Turkey
Beth Martin, 28, from Portsmouth, became 'delirious' on the first day of the trip and was placed in critical care.
She had been on holiday with her husband Luke and two children, aged eight and five but died around a day after she was taken into hospital on April 28, it was reported by the Daily Mail.
Her family claimed they were not informed about the serious nature of her condition and Turkish authorities had accused Luke of 'poisoning' his wife.
It emerged following a UK autopsy that Mrs Martin's heart had been removed following her death although no permission had been sought from her family, according to a family fundraiser.
A new report has indicated that the mother had died due to food poisoning, according to local media outlet Sozcu and found no evidence she died from 'traumatic effects'.
Findings, released by the Forensic Medicine Institution, said: 'It has been concluded that Martin's death occurred as a result of food poisoning and its complications.'
It reportedly added the full examination of Beth's heart had been completed.
Her devastated husband Luke previously said he has suffered the 'deepest level of trauma' following his wife's death and added that telling his children they would never see their mother again 'broke him'.
'Two weeks ago me, my wife and two kids set out for a family holiday to Turkey. Only three of us made it back,' Luke wrote on social media on May 11.
'I lost my wife, my children lost their mum, we lost the biggest piece of the puzzle that was our family.
'It has been the worst and most traumatic week of my entire life, and to top it off. I had to break the news to my babies that their mum isn't coming home, it broke me.'
Mrs Martin started to feel unwell after the family touched down at the airport in Turkey on Sunday, April 27, leading her husband to call for an ambulance the following day.
She was taken to a 'destitute' hospital where she was quickly transferred into intensive care.
It was claimed on a GoFundMe page, Mr Martin was 'banned' from seeing his wife and had not been updated on her condition as she was being cared for in hospital.
Doctors raised concerns at the time about Mrs Martin's heart but she died the day after being taken into hospital.
The family alleged they were made to carry her body in a bag throughout the hospital and claimed they were told they would have to wait more than a fortnight to repatriate her body so Luke 'paid thousands' for her to be flown home alongside him on the same flight.
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
39 minutes ago
- Medscape
Rheumatoid Nodules: Rare, Recurrent, and Still a Challenge
Despite the rising incidence of rheumatoid arthritis (RA), extra-articular manifestations have become rare in the era of modern treat-to-target therapy. However, they still present clinical challenges — particularly in the case of rheumatoid nodules. In addition to the need to rule out serious differential diagnoses and address potential complications, especially those involving the lungs, these recurrent inflammatory granulomas can affect daily life not only cosmetically but also functionally. Christopher Edwards, MD, professor of rheumatology at University Hospital Southampton in Southampton, England, discussed the clinical relevance and management of rheumatoid nodules during the 2025 Annual Meeting of the European Alliance of Associations for Rheumatology. When Edwards began his career in rheumatology, the presence of rheumatoid nodules was considered a key diagnostic criterion for RA. If not found on the hands, clinicians often examined the elbows and Achilles tendons, which are also common sites. Histologically, rheumatoid nodules are granulomatous inflammatory lesions that evolve through multiple stages. While often subcutaneous, they can also be found on the sclera, larynx, heart valves, and — most significantly — in the lungs. Biopsy When Malignancy Is Suspected Pulmonary nodules can present diagnostic difficulties. 'I've seen patients who were initially told they had lung metastases,' Edwards recalled. Waiting for further imaging and biopsy can be highly distressing for patients. Granulomatosis with polyangiitis can also resemble rheumatoid nodules, further complicating the diagnosis. It is especially important to distinguish these nodules from infections such as tuberculosis. Patients with RA are at increased risk for infection due to both the underlying disease and immunosuppressive treatment. Like tuberculomas, pulmonary rheumatoid nodules can undergo central necrosis when exposed to tumor necrosis factor-alpha inhibitors, leading to cavitation or even pneumothorax. 'Any cavity in the lung can become infected,' Edwards cautioned. Diagnosing Peripheral Nodules Diagnosing peripheral rheumatoid nodules is usually straightforward. These nodules typically feel rubbery on palpation and are movable relative to the underlying tissue. Important differential diagnoses include gouty tophi, lipomas, epidermoid cysts, infectious granulomas, sarcoidosis, and neoplastic lesions. Imaging tools such as ultrasound or fine-needle aspiration can help clarify the diagnosis, particularly when gout is suspected. 'Biopsy is rarely required — only if there's concern about a neoplastic or malignant process,' Edwards explained. Better Disease Control, Fewer Nodules 'In my practice, I see very few nodules these days,' said Edwards. Epidemiological data support this trend: The 10-year cumulative incidence of subcutaneous nodules in RA patients decreased from 30.9% between 1985 and 1999 to 15.8% between 2000 and 2014. Multiple factors likely contributed to this decline, including the earlier initiation of more effective therapies and a reduction in smoking rates. Smoking remains a major risk factor for nodule development, along with long-standing, severe RA, male sex, and seropositivity for rheumatoid factor or anti-cyclic citrullinated peptide antibodies. 'Patients with nodules are almost always seropositive,' Edwards noted. These findings suggest that maintaining tight control of disease activity is more critical for preventing nodules than concerns about drug-induced nodulosis. Little Reason to Discontinue Methotrexate 'There was a time when we worried that methotrexate might be causing nodules,' Edwards said, referring to anecdotal reports of increased nodulosis after initiating methotrexate (MTX). 'But now we're using more MTX and seeing fewer nodules.' He emphasized that the presence of nodules alone should not prompt discontinuation of MTX. 'It wasn't a reason to stop methotrexate back then, and it's not a reason now — though in some cases, it may justify a more aggressive treatment approach.' Other medications — particularly tumor necrosis factor inhibitors like etanercept — have also been linked to nodule development, though Edwards suggested this may reflect reporting bias. 'It might not be causal,' he said. Often, treatment isn't necessary. 'Sometimes it's just a matter of observation,' Edwards noted. Painful or functionally limiting nodules may be managed with local glucocorticoid injections to reduce discomfort and soften the nodules. However, he admitted he had never personally injected a rheumatoid nodule. He also cautioned against injections over the elbow. 'There's something about the skin and the olecranon bursa that makes infections more likely in that area. I saw one patient who needed plastic surgery after an infection left a significant wound.' Rheumatoid nodules also have a tendency to recur. When to Consider Surgery 'Surgery can benefit some patients,' Edwards said. Surgical removal may be warranted for nodules that ulcerate, become infected, or impair function — such as large nodules on the thumb or fingertip that interfere with gripping. 'Patients are usually happy to regain function, even if the nodule comes back a couple of years later.' Nodules that are consistently irritated by shoes or clothing straps may also merit removal. Pulmonary rheumatoid nodules — unlike subcutaneous ones — often contain B cells and typically respond well to rituximab or abatacept. 'These lung nodules tend to shrink or stabilize with rituximab, and certainly, no new ones seem to develop,' Edwards noted. Case reports and small series have also documented improvement with Janus kinase inhibitors.
Yahoo
an hour ago
- Yahoo
Why AstraZeneca Stock Topped the Market on Tuesday
American investors might not have to trade in the company's ADSes in the future. Its CEO is considering a shift in its listing, and even a potential move for its headquarters. 10 stocks we like better than AstraZeneca Plc › Trading in AstraZeneca's (NASDAQ: AZN) American Depositary Shares (ADSes) was lively on Tuesday, on news that its leadership intends to directly list its sock on a U.S. exchange. Investors clearly liked that idea, as they bid those ADSes up by more than 2% that trading session. With that rise, it did better than the S&P 500 (SNPINDEX: ^GSPC), which closed the day marginally (0.1%) lower. That morning, U.K. newspaper The Times published an article stating that AstraZeneca CEO Pascal Soriot aims to move the company's stock market listing onto our shores (ADSes are certificates conferring ownership of a stock, not the stock itself). Citing unidentified multiple sources, the newspaper wrote that Soriot might also be mulling a move of AstraZeneca's headquarters from the U.K. to the U.S. Currently, the global healthcare company is a component of the FTSE 100, considered by many to be the most important U.K. stock index. According to The Times' reporting, the chief executive is "known to be deeply frustrated with the U.K.'s operating environment." The newspaper added that he has publicly expressed concern about what he perceives to be a decline in European competitiveness against the U.S. and China. The pair happens to be the company's two largest markets. Neither Soriot nor AstraZeneca has yet officially commented on the article. Since AstraZeneca has quite a presence in the U.S. healthcare market and does much of its business in the country, it makes abundant sense to shift the main stock market listing and even the headquarters here. It's unclear (at least for now) how much this might affect the company's fundamentals and operations, but as a concept, it's a good idea. Before you buy stock in AstraZeneca Plc, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and AstraZeneca Plc wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $722,181!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $968,402!* Now, it's worth noting Stock Advisor's total average return is 1,069% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends AstraZeneca Plc. The Motley Fool has a disclosure policy. Why AstraZeneca Stock Topped the Market on Tuesday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
EU's Champions League: Sweden, Czech Republic, and Greece Score Big Against Smoking
WVA's trophy ceremony in front of the European Parliament BRUSSELS, Belgium, July 03, 2025 (GLOBE NEWSWIRE) -- Brussels turned into a Champions League arena for harm reduction as the World Vapers' Alliance (WVA) staged a trophy ceremony in front of the European Parliament, celebrating the real winners in the fight against smoking. Sweden, the Czech Republic, and Greece took centre stage, hoisting the 'Champions of Change' trophy for their remarkable victories in reducing smoking rates—while EU policymakers watched from the sidelines. 'Brussels is obsessed with prohibition and ignores the evidence right in front of them. Lives are being lost because the EU refuses to follow the science,' said WVA Director Michael Landl as he handed over the trophies. 'Instead of learning from countries that are saving lives, the EU is making life harder for smokers who want to quit.' Sweden claimed the top spot, becoming the world's first officially smoke-free nation with just 4.5% of Swedish-born adults smoking—a rate five times lower than the European average and achieved 16 years ahead of the EU's own target. The Czech Republic and Greece also took home silverware, having cut smoking rates by 23% and 14% respectively in the last three years through pragmatic, harm reduction-focused strategies. But while the champions celebrated on the podium, EU leaders remained stuck in the locker room. Irish Prime Minister Micheál Martin, ahead of Ireland's EU Council Presidency next year, outrageously claimed that vaping is as bad as the smoking phenomenon—signalling a worrying direction for future policy. WVA Policy Manager Alberto Gómez Hernández warned, 'The EU's refusal to recognise these achievements is a disservice to millions of Europeans who deserve better options to quit smoking.' With Commissioner Varhelyi confirming that the Tobacco Products Directive (TPD) will be revised this term, the WVA urged Brussels to stop missing open goals and start following the lead of Europe's true champions—before more lives are lost off the pitch. Contact:Michael Landl info@ A photo accompanying this announcement is available at in to access your portfolio
